This project represents a unique opportunity to establish a nanotechnology-based anticancer drug development program using Brazilian chemical species, aiming at validating of lead compounds for the development of safer and more specific chemotherapeutic agents. By addressing the increasingly importance of world-wide cancer epidemiology, our unique experience in prospecting biologically active compounds and integration with state-of-the-art drug formulation/drug carrier technologies, this project has a high probability of producing new knowledge, new intellectual property and, most importantly, new anti-cancer drugs with significant therapeutic potential. It may favor the pharmacological innovation in Brazilian academy and industry. In the long run, this scenario may encourage scientific progress and creation of new products with significant commercial potential.
Funded by: Department of Foreign Affairs, Trade and Development